Laropiprant

From Ganfyd

Jump to: navigation, search

An antiflushing agent which when combined with nicotinic acid (Tredaptive®, Pelzont® or Trevaclyn®) failed to have net benefit in hyperlipidaemia.[1].

References

  1. [http://www.ema.europa.eu/docs/en_GB/document_library/Referrals_document/Tredaptive_20/Recommendation_provided_by_Pharmacovigilance_Risk_Assessment_Committee/WC500137124.pdf EMEA Q&A PRAC considers that benefit-risk balance of Tredaptive, Pelzont and Trevaclyn (nicotinic acid/laropiprant) is negative 10 Jan 2013
Personal tools